MIRM - Mirum Pharmaceuticals, Inc.
IEX Last Trade
42.1
-0.030 -0.071%
Share volume: 5,773
Last Updated: Thu 26 Dec 2024 08:29:44 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$42.13
-0.03
-0.07%
Fundamental analysis
9%
Profitability
0%
Dept financing
17%
Liquidity
74%
Performance
0%
Performance
5 Days
1.05%
1 Month
-6.60%
3 Months
8.97%
6 Months
28.33%
1 Year
39.40%
2 Year
139.74%
Key data
Stock price
$42.10
DAY RANGE
$41.54 - $42.32
52 WEEK RANGE
$24.00 - $48.89
52 WEEK CHANGE
$40.75
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Christopher Peetz
Region: US
Website: mirumpharma.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mirumpharma.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Mirum Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease.
Recent news